| Literature DB >> 31382665 |
Chiara Emma Campiglio1,2, Nicola Contessi Negrini1,2, Silvia Farè1,2, Lorenza Draghi3,4.
Abstract
Electrospinning is an exceptional technology to fabricate sub-micrometric fiber scaffolds for regenerative medicine applications and to mimic the morphology and the chemistry of the natural extracellular matrix (ECM). Although most synthetic and natural polymers can be electrospun, gelatin frequently represents a material of choice due to the presence of cell-interactive motifs, its wide availability, low cost, easy processability, and biodegradability. However, cross-linking is required to stabilize the structure of the electrospun matrices and avoid gelatin dissolution at body temperature. Different physical and chemical cross-linking protocols have been described to improve electrospun gelatin stability and to preserve the morphological fibrous arrangement of the electrospun gelatin scaffolds. Here, we review the main current strategies. For each method, the cross-linking mechanism and its efficiency, the influence of electrospinning parameters, and the resulting fiber morphology are considered. The main drawbacks as well as the open challenges are also discussed.Entities:
Keywords: cross-linking; electrospinning; gelatin; nanofibers; natural polymers; regenerative medicine; scaffold; soft tissues; tissue engineering
Year: 2019 PMID: 31382665 PMCID: PMC6695673 DOI: 10.3390/ma12152476
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1Processing of collagen for gelatin extraction. Collagen, characterized by a triple-helix structure and insolubility, is processed either by acid (gelatin A) or alkaline (gelatin B) pre-treatment. After extraction, purification, and recovery, gelatin, a soluble product, is obtained. When dissolved in water, gelatin undergoes a reversible sol-gel transition by heat–cool process.
Examples of cross-linking methods used for the production of gelatin hydrogels. The cross-linking methods are divided in three categories, physical, chemical, and enzymatic. For each example, the cross-linking methods, gelatin type, and gelatin concentration used are reported.
| Cross-Linking Method | Gelatin Type | Gelatin Concentration (w/v) | Reference |
|---|---|---|---|
|
| |||
| High energy electron beam | type A | 2–20% | Wisotzki et al. 2014 [ |
| type B | 10% | Van Vlierberghe 2016 [ | |
| type A, type B and cold fish skin gelatin | 1–30% | Terao et al. 2012 [ | |
| γ-irradiation | type A | 3% | Cataldo et al. 2008 [ |
| type B | 1–20% | Kojima et al. 2004 [ | |
| Plasma treatment | type A | 1.25–2.5% | Prasertsung et al. 2013 [ |
| Dehydrothermal treatment | type A | 3% | Hussain et al. 2014 [ |
| type B | 10% | Omata et al. 2014 [ | |
| type A | 10% | Prasertsung et al. 2010 [ | |
|
| |||
| EDC/NHS 1 | type A and B | 10% | Kuijpers et al. 2012 [ |
| type A | 10% | Claaßen et al. 2017 [ | |
| type B | 3% | Rodriguez et al. 2016 [ | |
| type B | 10% | Gorgieva et al. 2014 [ | |
| Formaldehyde | type B | 2% | Ninan et al. 2013 [ |
| Glutaraldehyde | - | 5% | Fan et al. 2018 [ |
| type B | 20% | Poursamar et al. 2016 [ | |
| Genipin | type A | 2–10% | Kirchmajer et al. 2013 [ |
| - | 10% | Wu et al. 2013 [ | |
| - | 8% | Liang et al. 2004 [ | |
| - | 10% | Focaroli et al. 2014 [ | |
| Irgacure 2959 + UV light 2 | type B | 5–20% | Zhao et al. 2016 [ |
| type B | 10% | Van Nieuwenhove et al. 2016 [ | |
| type B | 10% | Zhou et al. 2014 [ | |
| type A | 5–10% | Celikkin et al. 2017 [ | |
| type A | 15–25% | Contessi Negrini et al. 2019 [ | |
| Isophorone diisocyanate | - | 6% | Subramanian et al. 2013 [ |
| Ethylene glycol diglycidyl ether | type B | 15% | Vargas et al. 2008 [ |
|
| |||
| Microbial transglutaminase | type A | 10% | Yung et al. 2007 [ |
| type A | 4% | Broderick et al. 2004 [ | |
| type A | 1–10% | Yang et al. 2016 [ | |
1 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/N-hydroxysuccinimide. 2 Gelatin was chemically modified by methacrylate groups, subsequently cross-linked by using a photo initiator and UV light.
Figure 2Schematic illustration of representative cross-linking methods used to fabricate gelatin hydrogels.
Figure 3Schematic representation of cross-linking strategies used for the stabilization of electrospun gelatin matrices. Physical cross-linking can be performed by high energy electron beam, plasma treatment, or dehydrothermal treatment. Chemical cross-linking can be performed by immersion in a cross-linking solution, by using vapors of the cross-linker, or by chemically modifying gelatin to subsequently cross-link it by UV irradiation.
Cross-linking strategies employed in the stabilization of electrospun gelatin nanofibers. Strategies are divided by physical and chemical methods. The type of gelatin and the main parameters involved in the cross-linking process are reported, as well as the final aim of the study.
|
| |||||||
|
|
|
|
| ||||
|
|
|
|
| ||||
|
| type B | 10–300 kGy | 1 MeV | 17 mA | 8.33 kGy/s | Soft tissue engineering | Lee et al. [ |
|
|
|
|
| ||||
|
|
|
|
| ||||
|
| - | Low | Oxygen | 2 min | Non-equilibrium | Tissue engineering | Sisson et al. 2009 [ |
| type A, B | Low | Argon | - | Non-equilibrium Pulsed inductively coupled | Biomedical | Ratanavaraporn et al. 2010 [ | |
| type A | Atmospheric | Air | 20 min | Non-equilibrium | Tissue engineering | Liguori et al. 2016 [ | |
|
|
|
|
| ||||
|
|
| ||||||
|
| type A, B | 140 °C | 48 h | Biomedical | Ratanavaraporn et al. 2010 [ | ||
| Fish | 140 °C | 24/48/72 h | Tissue engineering | Gomes et al. 2013 [ | |||
| type A | 160 °C | 48 h | Tissue engineering | Ghassemi and Slaughter 2018 [ | |||
|
| |||||||
|
|
|
|
| ||||
|
|
|
|
| ||||
|
| type A | EDC = 50 mM | EtOH/dH2O 8/2 | 24 h | 4 °C | Biomedical | Li et al. 2006 [ |
| - | EDC = 5/25/50/75 mM | EtOH/dH2O 9/1 | 24 h | 4 °C | Periodontal tissue regeneration/Cornea regeneration | Zhang et al. 2009 [ | |
| type A, B | EDC = 14 mM | EtOH or dH2O | 2 h | - | Biomedical | Ratanavaraporn et al. 2010 [ | |
| type B | EDC = 2 M | EtOH/dH2O 9/1 | 7 h | - | Tissue engineering | Ghassemi and Slaughter 2018 [ | |
| type A | EDC = 5 mM/mg sample | EtOH/dH2O (80–99.5 vol%) | 48 h | 25 °C | Ophthalmic | Chou et al. [ | |
|
| type A | 5–7% | EtOH | 3–7 days | 37 °C | Tissue engineering | Panzavolta et al. 2011 [ |
| - | 0.1–0.5% | EtOH | 3 days | 37 °C | Angiogenesis in Tissue engineering | Del Gaudio et al. 2013 [ | |
| - | 0.1–2% | EtOH/dH2O 70% | 19 h | - | Tissue engineering | Sisson et al. 2009 [ | |
| Fish | 2% | EtOH/dH2O 90% | 1–5 days | - | Tissue engineering | Gomes et al. 2013 [ | |
|
| type A | 25% | 10 mL dH2O | 6–12 h | - | Biomedical | Zhang et al. 2006 [ |
| - | 0.5% | - | 19 h | - | Tissue engineering | Sisson et al. 2009 [ | |
| type A | 25% | 20 mL dH2O | 2–4–6–8–10 min | - | Drug delivery | Laha et al. 2016 [ | |
| type A | 10% | - | 2 h | - | Vascular tissue engineering | Y. Elsayed et al. 2016 [ | |
| type A | 25% | - | 2 h | - | Vascular tissue engineering | Yahya Elsayed et al. 2016 [ | |
| Fish | 2.5% | In situ | 8 h | - | Tissue engineering | Zhan et al. 2016 [ | |
| Fish | 5% | 10 mL dH2O | 1–24 h | 40 °C | Tissue engineering/Skin regeneration | Gomes et al. 2013 [ | |
| type A | 50% | 20 mL dH2O | 1–3 h | 37 °C | Wound healing | Rujitanaroj et al. 2008 [ | |
| type A | 0.05% | In situ | - | - | Tissue engineering | Nguyen et al. 2010 [ | |
| - | 50% | - | 3–24 h | - | Drug delivery | Lakshminarayanan et al. 2014 [ | |
| - | 50% | - | 15–45–90–360 min | 25 °C | Tissue engineering | Wu et al. 2011 [ | |
|
| type B | 0.1–5% | 10 mL t-BuOH | 1 h crosslink + freeze-dry | 30 °C | Cartilage tissue regeneration | Skotak et al. 2010 [ |
|
| - | 0.1–0.5% | EtOH 70% | 19 h | Room temp | Tissue engineering | Sisson et al. 2009 [ |
| Gelatin + PLLA | 0.5–0.7% | EtOH 70% | 19 h | Room temp | Nervous tissue regeneration | Binan et al. 2014 [ | |
|
| type A | 2–4–6% | In situ | 24–48–72 h | Room temp | Skin regeneration | Dias et al. 2017 [ |
|
| type A | 1x, 5x, 10x ratio of isocyanate/amine | In situ | 3 h | Room temp | Tissue engineering | Kishan et al. 2015 [ |
|
| type A | 0.5–1–2–3–4–5% | EtOH 75% | 1–6 days | 20–30–40–50–60 °C | Tissue engineering | Chen et al. [ |
|
| type A | 0.1–0.5–1–2% | EtOH | 1–3–5 days | 37 °C | - | Jalaja et al. 2015 [ |
|
|
|
|
| ||||
|
|
| ||||||
|
| type A | 92 μL/gramgelatin | In situ | Peripheral nerve regeneration | Tonda-Turo et al. 2013 [ | ||
|
| type A | 10% | 30 min (immersion + UV light) | Skin regeneration | Sun et al. 2017 [ | ||
| GelMA + PCL | 0.015% | 20 min (immersion) | Tissue engineering | Ferreira et al. 2017 [ | |||
| type A | 10% | 2 h (immersion) | Wound healing | Zhao et al. 2017 [ | |||
|
|
|
|
| ||||
|
| Gel + Poly (acrylic acid-g-azidoaniline) | Two UV lamp (18 W) during electrospinning process (in situ) | Tissue engineering | Lin and Tsai 2013 [ | |||
Figure 4Morphology of electrospun gelatin nanofibers cross-linked with different strategies: (a) Plasma treatment (scale bar: 5 μm; reprinted from [71]), (b) dehydrothermal treatment (scale bar: 10 μm; reprinted from [54] with permission of Elsevier), (c) EDC/NHS (scale bar = 10 μm; reprinted from [72] with permission of John Wiley and Sons), (d) genipin (scale bar: 1 μm; reprinted from [78] with permission of Elsevier), (e) glutaraldehyde vapor (scale bar: 10 μm; reprinted from [54] with permission of Elsevier), (f) glutaraldehyde solution (scale bar: 5 μm; reprinted from [90] with permission of John Wiley and Sons), (g) glyceraldehyde (scale bar: 1 μm reprinted from [70] with permission of ACS Publications), and (h) Irgacure 2959 with UV treatment (scale bar: 5 μm reprinted from [98] with permission of Elsevier).
Figure 5Tissue engineering applications of electrospun cross-linked gelatin matrices. (a) Cell infiltration inside electrospun gelatin vs. GelMA scaffolds (phalloidin staining, Alexa Fluor 488; scale bar: 50 μm) and (b) in vivo assessment of electrospun gelatin and GelMA scaffold skin regenerative potential by histological analysis (scale bar: 200 and 100 μm); reprinted from [100] with permission of Elsevier. (c) Confocal images of primary Schwann cells cultured on random and aligned electrospun gelatin matrices (vs. tissue culture plastic as control; scale bar: 40 μm) [97]. (d) SEM micrographs of human umbilical vein smooth muscle cells cultured on electrospun gelatin matrices for smooth muscle regeneration in vascular tissue engineering; reprinted from [83] with permission of John Wiley and Sons.
Figure 6Future perspectives and open challenges in the fabrication of electrospun gelatin scaffolds.